Mesenchymal Stromal Cells: Clinical Challenges and Therapeutic Opportunities
Jacques Galipeau,Luc Sensebé +1 more
1.4K
TL;DR: Important biological and pharmacological disparities in pre-clinical research and human translational studies are highlighted, and analyses of clinical trial failures and recent successes provide a rational pathway to MSC regulatory approval and deployment for disorders with unmet medical needs.
read more
About: This article is published in Cell Stem Cell. The article was published on 01 Jun 2018. and is currently open access. The article focuses on the topics: Animal data & Clinical trial.
read more
Chat with Paper
AI Agents for this Paper
Find similar papers on Google Scholar, PubMed and Arxiv
Write a critical review of this paper
Analyze citations of this paper to find unaddressed research gaps
Citations
Cytokine storm and leukocyte changes in mild versus severe SARS-CoV-2 infection: Review of 3939 COVID-19 patients in China and emerging pathogenesis and therapy concepts.
TL;DR: Examining leukocyte and cytokine activity in COVID‐19 focuses on how these levels are altered as the disease progresses and proposed consequences to organ pathology and Viral and host interactions are described to gain further insight into leukocytes biology and how dysregulated cytokine responses lead to disease and/or organ damage.
744
Mesenchymal Stem Cell Immunomodulation: Mechanisms and Therapeutic Potential.
TL;DR: The immunomodulatory aspects of naïve and engineered MSCs are reviewed, strategies for increasing the potential of successfully using MSCesenchymal stem/stromal cells in clinical settings are discussed, and efforts to improve this situation are discussed.
652
Treatment with allogeneic mesenchymal stromal cells for moderate to severe acute respiratory distress syndrome (START study): a randomised phase 2a safety trial.
Michael A. Matthay,Carolyn S. Calfee,Hanjing Zhuo,B. Taylor Thompson,Jennifer G. Wilson,Joseph E. Levitt,Angela J. Rogers,Jeffrey E. Gotts,Jeanine P. Wiener-Kronish,Ednan K. Bajwa,Michael P. Donahoe,Bryan J. McVerry,Luis A. Ortiz,Matthew C. Exline,John W. Christman,Jason Abbott,Kevin L. Delucchi,Lizette Caballero,Melanie McMillan,David H. McKenna,Kathleen D. Liu +20 more
TL;DR: One dose of intravenous MSCs was safe in patients with moderate to severe ARDS, and the viability of M SCs must be improved.
574
Shattering barriers toward clinically meaningful MSC therapies.
Oren Levy,Rui Kuai,Rui Kuai,Erika M. J. Siren,Deepak Bhere,Yuka Milton,Nabeel Nissar,Michael De Biasio,Martina Heinelt,Brock Reeve,Reza Abdi,Meshael Alturki,Mohanad Fallatah,Abdulaziz Almalik,Ali H. Alhasan,Khalid Shah,Khalid Shah,Jeffrey M. Karp +17 more
TL;DR: The major clinical challenges with MSC therapies, the details of these challenges, and the potential bioengineering approaches that leverage the unique biology of MSCs to overcome the challenges and achieve more potent and versatile therapies are discussed.
540
Biological functions of mesenchymal stem cells and clinical implications
Abderrahim Naji,Masamitsu Eitoku,Benoit Favier,Frédéric Deschaseaux,Nathalie Rouas-Freiss,Narufumi Suganuma +5 more
TL;DR: The fundamental and advanced concepts of MSC biological features are outlined and the biological functions of M SCs in their basic and translational aspects in therapy for degenerative and/or inflammatory diseases are underlined.
534
References
Safety Profile of Good Manufacturing Practice Manufactured Interferon γ-Primed Mesenchymal Stem/Stromal Cells for Clinical Trials.
Adam J. Guess,Beth Daneault,Rongzhang Wang,Hillary Bradbury,Krista M. D. La Perle,James Fitch,Sheri L. Hedrick,Elizabeth Hamelberg,Caroline Astbury,Peter White,Kathleen Overolt,Hemalatha G. Rangarajan,Rolla Abu-Arja,Steven M. Devine,Satoru Otsuru,Massimo Dominici,Lynn O'Donnell,Edwin M. Horwitz +17 more
TL;DR: A Good Manufacturing Practice‐compliant two‐step MSC manufacturing protocol to generate MSCs or interferon γ (IFNγ) primed MSCS which allows freshly expanded cells to be infused in patients on a predetermined schedule and demonstrates the feasibility of priming the cells with any biologic agent.
62
Conditional Approval: Japan Lowers the Bar for Regenerative Medicine Products
TL;DR: A new system for conditional approval of regenerative medicine products will allow products of undetermined efficacy to enter the Japanese market.
60